Replimune Group (REPL)
(Delayed Data from NSDQ)
$9.86 USD
+0.13 (1.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $9.85 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
REPL 9.86 +0.13(1.34%)
Will REPL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REPL
Replimune (REPL) Gains on Positive Data From Melanoma Study
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Other News for REPL
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Replimune announces first patient dosed in IGNYTE-3 trial
Replimune Group price target lowered by $3 at JPMorgan, here's why
Replimune Group (REPL) Gets a Buy from Barclays